GSK plc and United Therapeutics Corporation: A Comprehensive Revenue Analysis

Pharma Giants' Revenue Growth: A Decade in Review

__timestampGSK plcUnited Therapeutics Corporation
Wednesday, January 1, 2014230060000001288519000
Thursday, January 1, 2015239230000001465761000
Friday, January 1, 2016278890000001598800000
Sunday, January 1, 2017301860000001725300000
Monday, January 1, 2018308210000001627800000
Tuesday, January 1, 2019337540000001448800000
Wednesday, January 1, 2020340990000001483300000
Friday, January 1, 2021341140000001685500000
Saturday, January 1, 2022293240000001936300000
Sunday, January 1, 2023303280000002327500000
Loading chart...

Infusing magic into the data realm

Revenue Trends of GSK plc and United Therapeutics Corporation

In the ever-evolving pharmaceutical industry, revenue growth is a key indicator of a company's success. From 2014 to 2023, GSK plc and United Therapeutics Corporation have shown distinct revenue trajectories. GSK plc, a global healthcare giant, saw its revenue grow by approximately 32% over this period, peaking in 2021 with a 48% increase from its 2014 figures. However, a slight dip in 2022 was followed by a recovery in 2023, reaching nearly 30 billion. In contrast, United Therapeutics Corporation, a leader in biotechnology, experienced a remarkable 81% revenue increase, culminating in 2023. This growth underscores the company's innovative approach and strategic market positioning. These trends highlight the dynamic nature of the pharmaceutical sector, where strategic decisions and market conditions play pivotal roles in shaping financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025